- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Severe active rheumatoid arthritis
- Meeting Date: July 2018
- Public Summary Document (PSD) July 2018 PBAC Meeting - PDF
- Public Summary Document (PSD) July 2018 PBAC Meeting - Word
Tocilizumab – July 2018
Tocilizumab: Injection 162 mg in 0.9 ml pre-filled pen; Actemra® Subcutaneous Injection
Last updated
26 October 2018